RSV Seasonal Vaccine Introduction and Growth Strategy slide image

RSV Seasonal Vaccine Introduction and Growth Strategy

H2 2024 Q3 and Year-to-date 2024 results Full-year and Q4 2024 results Performance vs BIU 20211 Guidance 2025 Investor roadmap over next 18 months Execution Portfolio phase III and regulatory decisions² Q2 2023 Q2 and Half-year 2023 results Full-year 2023 upgraded guidance ✓ Therapy Area Strategy R&D priorities Arexvy US KK regulatory approval ☑ Arexvy second season data • BELLUS Health, Inc. acquisition completed SCYNEXIS, Inc. exclusive license Q3 2023 Q3 and Year-to-date 2023 results Arexvy RSV, ≥60 YOA (JP) Arexvy, RSV, 50-59 YoA • Q4 2023 Full-year and Q4 2023 results Performance vs BIU 20211 Full-year 2024 guidance cabotegravir (long-acting), pre-exposure (EU) Vocabria, HIV treatment (CN) momelotinib MOMENTUM, myelofibrosis (US) Jemperli RUBY, 1L DMMR/MSI-H EC³ (US) Blenrep DREAMM-7/8, 2L+ multiple myeloma ° H1 2024 Q1 2024 results Q2 and Half-year 2024 results MenABCWY 1st gen (US, EU) 4 ° gepotidacin EAGLE-1, GC • momelotinib MOMENTUM, myelofibrosis (EU, JP) • Jemperli RUBY, 1L dMMR/MSI-H EC² (EU) • • Zejula FIRST IL maintenance ovarian cancer • Jemperli RUBY Part 2, 1L EC³ • • Capital Allocation and Distribution Investor Engagement completed Capital allocation R&D and BD priorities TA priorities GSK K > > > Full-year 2023 dividend declaration Meet the management, Oncology Roadshows Meet the Meet the Meet the management, management, HIV Infectious Diseases ☑ management, Respiratory/ Immunology Medical congresses Arexvy, RSV, 50-59 YOA (US, EU, JP) gepotidacin EAGLE-2/3, uUTI (US, EU) Nucala, nasal polyposis (JP) Nucala, severe asthma (CN) Nucala MATINEE, COPD depemokimab SWIFT-1/2, severe eosinophilic asthma depemokimab ANCHOR-1/2, CRSWNP Zejula ZEAL, IL maintenance NSCLC cobolimab COSTAR, 2L NSCLC Full-year 2024 dividend declaration 1. June 2021 Investor Update 2. Includes phase III data readouts and regulatory decisions with the applicable geography denoted in brackets 3. Endometrial cancer 4. Regulatory submission and acceptance 27 22
View entire presentation